Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.
Press releases published on August 7, 2025
Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
GlobeNewswire
·
August 7, 2025
SEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
GlobeNewswire
·
August 7, 2025
Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved alignment …
Verano Announces Resignation of Company President Darren Weiss
GlobeNewswire
·
August 7, 2025
CHICAGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the resignation of Darren Weiss from his role as Company President to …
1.2 Million Healthcare Devices and Systems Found Exposed Online - Patient Records at Risk of Exposure, Latest Research from Modat
GlobeNewswire
·
August 7, 2025
THE HAGUE, The Netherlands, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Over 1.2 million internet-connected healthcare devices and systems with exposure that endanger patient data shown in new research by European cybersecurity company Modat. #1 in our findings 174K …
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewswire
·
August 7, 2025
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter …
LENSAR Reports Second Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
18 ALLY Robotic Cataract Laser Systems™ (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide …
ProQR Announces Second Quarter 2025 Operating and Financial Results
GlobeNewswire
·
August 7, 2025
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseases Advancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett Syndrome Hosting fall Analyst and Investor Event (virtual), featuring detailed …
EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025
GlobeNewswire
·
August 7, 2025
Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT AUSTIN, Texas, August 7, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its …
Immunocore reports second quarter financial results and provides a business update
GlobeNewswire
·
August 7, 2025
KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial expected in 2H 2025 Phase 1 single …
Nusano Establishes Strategic Advisory Board to Support Innovation Across Company’s Product Verticals
GlobeNewswire
·
August 7, 2025
WEST VALLEY CITY, Utah, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the formation of a Strategic Advisory Board and the appointment of its first three members. The Board will …
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 7, 2025
CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalertinib REZILIENT1 …
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
GlobeNewswire
·
August 7, 2025
Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026 VAV1-directed …
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
GlobeNewswire
·
August 7, 2025
Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6. …
Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance
GlobeNewswire
·
August 7, 2025
-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a 63% increase compared to June 30, 2024 -- -- …
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part …
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 7, 2025
Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune …
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
GlobeNewswire
·
August 7, 2025
RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025 Phase 2 trial of RAP-219 in bipolar mania has been initiated and is enrolling patients; trial remains on track, …
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 7, 2025
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at 40% at the 75 µg Dose Level and at 50% at the 100 µg Dose …
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
GlobeNewswire
·
August 7, 2025
Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026 Rita Jain, M.D. appointed to Board of Directors Cash and short-term investments of approximately $113 million as of June 30, 2025 expected to …
Tilray Brands Launches The Humble Seed Whole Wheat Protein Crackers at Whole Foods Market
GlobeNewswire
·
August 7, 2025
NEW YORK and WINNIPEG, Manitoba, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Humble Seed, a better-for-you snack brand from Tilray Wellness a subsidiary of Tilray Brands, Inc. (“Tilray”) (NASDAQ: TLRY; TSX: TLRY), today announced the launch of its new Whole …